Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-03-17
1997-04-22
Dees, Jos e G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544354, A61K 31495, C07D24152
Patent
active
056229526
ABSTRACT:
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal.
Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.
REFERENCES:
patent: 3962440 (1976-06-01), St. Clair et al.
patent: 3992378 (1976-11-01), St. Clair et al.
patent: 4312807 (1982-01-01), Fuchs
patent: 4659713 (1987-04-01), Hass
patent: 4803270 (1989-02-01), Takemoto
patent: 4812458 (1989-03-01), Honor e et al.
patent: 4889855 (1989-12-01), Jacobsen et al.
patent: 4912108 (1990-03-01), Jacobsen et al.
patent: 4948794 (1990-08-01), Honore et al.
patent: 4975430 (1990-12-01), Jahr et al.
patent: 4977155 (1990-12-01), Jacobsen et al.
patent: 4994460 (1991-02-01), Dextraze et al.
patent: 5026704 (1991-06-01), Honore et al.
patent: 5055465 (1991-10-01), Davey
patent: 5055470 (1991-10-01), Boissard et al.
patent: 5057516 (1991-10-01), Jacobsen et al.
patent: 5061706 (1991-10-01), Honore e et al.
patent: 5075306 (1991-12-01), Jacobsen et al.
patent: 5079250 (1992-01-01), Jacobsen et al.
patent: 5081123 (1992-01-01), Honor e et al.
patent: 5109001 (1992-04-01), Jacobsen et al.
patent: 5166155 (1992-11-01), Jorgensen et al.
patent: 5187171 (1993-02-01), Cordi
patent: 5190941 (1993-03-01), Nozulak et al.
patent: 5196421 (1993-03-01), McQuaid et al.
patent: 5198461 (1993-03-01), W atjen et al.
patent: 5268378 (1993-12-01), Baker et al.
patent: 5283244 (1994-02-01), Sakamoto et al.
patent: 5308845 (1994-05-01), Honor e et al.
patent: 5352683 (1994-10-01), Mayer et al.
Yamada et al., "Quantitative Physiological Characterization of a Quinoxalinedione non-NMDA Receptor Antagonist", J. Neurosci. 9:3230-3236 (Sep. 1989).
Yoneda & Ogita, "Abolition of the NMDA-Mediated Responses by a Specific Glycine Antagonist, 6, 7-Dichloroquinoxaline-2, 3-Dione (DCQX)", Biochem. & Biophys. Res. Comm. 164:841-849 (Oct. 31, 1989).
Vaccarino et al., "NMDA Receptor Antagonists, MK-801 and ACEA-1011, Prevent the Development of Chronic Pain Following Subcutaneous Formalin," Brain Research 615:331-334 (Jul. 2, 1993).
Warner et al., "Glycine NMDA Receptor Antagonists Reduce Focal But Not Global Ischemic Brain Damage in the Rat," Soc. Neurosci. Abs. 19:1646, Abstract No. 674.3 (Nov. 1993).
White et al., "Anticonvulsant Profile and Therapeutic Potential of N-Methyl-D-Aspartic Acid and Strychnine-Insensitive Glycine Antagonists," Epilepsia 32. Suppl. 3:12 (Dec. 1991).
Louvet et al., "Novel benzimidazoles as ligands for the strychnine-insensitive N-methyl-D-aspartate-linked glycine receptor", Eur. J. Med. Chem. 28:71-75 (Apr. 1993).
McFarlane & Smith, "A New Route to N-Hydroxyquinoxaline-2, 3-diones and some AZA-Analogues", Tetrahedron Lett. 28:6363-6366 (1987).
McQuaid et al., "3-Phenyl-4-hydroxyquinolinin-2 (1H)-ones: Potent and Selective Antagonists at the Strychnine-Insensitive Glycine Site on the N-Methyl-D-asparate Receptor Complex," J. Med. Chem. 35:3423-3425 (Sep. 1992).
McQuaid et al., "Synthesis and Excitatory Amino Acid Pharmacology of a Series of Heterocyclic-Fused Quinoxalinones and Quinazolinones", J. Med. Chem. 35:3319-3324 (Sep. 1992).
Moore et al., "Anticonvulsant Activity of Glycine-Site NMDA Antagonists", Bioorg. & Med. Chem. Lett. 3:61-64 (Jan. 1993).
N asstr om et al., "Antinociceptive actions of different classes of excitatory amino acid receptor antagonists in mice", Eur. J. Pharmacol. 212:21-29 (Feb. 1992.
Ogita & Yoneda, "6, 7-Dichloroquinoxaline-2, 3-Dione is a Competitive Antagonist Specific to Strychnine-Insensitive [.sup.3 H] Glycine Binding Sites on the N-Methyl-D-Aspartate Receptor Complex", J. Neurochem. 54:699-702 (1990).
Patel et al., "6, 7-Dinitroquinoxaline-2, 3-Dione Blocks the Cytotoxicity of N-Methyl-D-Aspartate and Kainate, but Not Quisqualate, in Cortical Cultures", J. Neurochem. 55:114-121 (1990).
Pellegrini-Giampietro et al., "Quinoxalines interact with the glycine recognition site of NMDA receptors: studies in guinea-pig myenteric plexus and in rat cortical membranes", Br. J. Pharmacol. 98:1281-1286 (1989).
Randle et al., "Competitive inhibition of NBQX of kainate/AMPA receptor currents and excitatory synaptic potentials: importance of 6-nitro substitution", Eur. J. Pharmacol. 215:237-244 (May, 1992).
Randle et al., "Quinoxaline Derivatives: Structure-Activity Relationships and Physiological Implications of Inhibition of N-Methyl-D-aspartate and Non-N-methyl-D-aspartate Receptor-Mediated Currents and Synaptic Potentials", Mol. Pharmacol. 41:337-345 (Feb. 1992).
Rao et al., "6, 7-Dinitroquinoxaline-2, 3-Dione and 6-Nitro, 7-Cyanoquinoxaline-2, 3-Dione Antagonize responses mediated by N-methyl-D-aspartate and NMDA-associated Glycine recognition sites in vivo: measurements of cerebellar cyclic-GMP", Neuropharmacol. 29:1031-1035 (Nov. 1990).
Rowley et al., "3-Acyl-4-hydoxyquinolin-2(1H)-ones. Systemically Active Anticonvulsants Acting by Antagonism at the Glycine Site of the N-Methyl-D-Aspartate Receptor Complex", J. Med. Chem. 36:3386-3396 (Oct. 1993).
Salituro et al., "3-(2-Carboxyindol-3-yl)propionic Acid-Based Antagonists of the N-Methyl-D-aspartic Acid Receptor Associated Glycine Binding Site," J. Med. Chem. 35:1791-1799 (May, 1992).
Schoepp et al., "Excitatory Amino Acid-Induced Convusions in Neonatal Rats Mediated by Distinct Receptor Subtypes," Eur. J. Pharmacol. 182:421-427 (1990).
Sheardown et al., "A potent antagonist of the strychnine insensitive glycine receptor has anticonvulsant properties", Eur. J. Pharmacol. 174:197-204 (1989).
Smith et al., "Structure-Activity Relationships of a Series of Glycine antagonists related to 5,7-Dichlorokynurenic Acid and 3-(2-carboxy-6-chloroindol-3-yl)Acetic Acid", Bioorg. & Med. Chem. Lett. 3:81-84 (Jan. 1993).
Turski et al., "Relief of Experimental Spasticity and Aniolytic/Anticonvulsant Actions of the Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionate Antagonist 2,3-Dihydroxy-6-Nitro-7-Sulfamoyl-Benzo(F) Quinoxaline," J. Pharm. Exp. Ther. 260:742-747 (Feb. 1992).
Kay & Ikeda, "The quinoxalinediones antagonise the visual firing of sustained retinal ganglion cells", Eur. J. Pharmacol. 164:381-384 (1989).
Kehne et al., "NMDA Receptor Complex Antagonists have Potential Anxiolytic Effects as Measured with Separation-Induced Ultrasonic Vocalization," Eur. J. Pharmacol. 193:283-92 (Feb. 1991).
Kemp & Leeson, "The glycine site of the NMDA receptor-five years on", TiPS 14:20-25 (Jan. 1993).
Kessler et al., "A Glycine Site Associated with N-Methyl-D-Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists", J. Neurochem. 52:1319-1328 (1989).
Kessler et al., "Quinoxaline derivatives are high-affinity antagonists of the NMDA receptor-associated glycine sites", Brain Res. 489:377-382 (1989).
Kleckner & Dingledine, "Selectivity of Quinoxalines and Kynurenines as Antagonists of the Glycine Site on N-Methyl-D-aspartate Receptors", Mol. Pharmacol. 36:430-436 (1989).
Kulagowski et al., "3'-(Arylmethyl)-and 3'-(Aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: Orally Active Antagonists of the Glycine Site on the NMDA Receptor," J. Med. Chem 37:1402-1405 (May 1994).
Leeson and Iversen, "The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential," J. Med. Chem. 37:4053-4067 (Nov. 1994).
Leeson et al., "Amino Acid Bioisosteres: Design of 2-Quinolone Derivatives as Glycine-Site N-Methyl-D-aspartate Receptor Antagonists", Bioorg. & Med. Chem. Lett. 3:299-304 (Mar. 1993).
Leeson
Keana John F. W.
Weber Eckard
Cebulak Mary C.
Dees Jos e G.
State of Oregon acting by and through the Oregon State Board of
The Regents of the University of California
LandOfFree
Glycine receptor antagonists and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycine receptor antagonists and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycine receptor antagonists and the use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-341755